IL244277A0 - Methods and preparations of attaching an antibody to a specific location - Google Patents

Methods and preparations of attaching an antibody to a specific location

Info

Publication number
IL244277A0
IL244277A0 IL244277A IL24427716A IL244277A0 IL 244277 A0 IL244277 A0 IL 244277A0 IL 244277 A IL244277 A IL 244277A IL 24427716 A IL24427716 A IL 24427716A IL 244277 A0 IL244277 A0 IL 244277A0
Authority
IL
Israel
Prior art keywords
compositions
site
specific antibody
antibody conjugation
conjugation methods
Prior art date
Application number
IL244277A
Other languages
English (en)
Hebrew (he)
Original Assignee
Stemcentrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52587354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL244277(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2014/053014 external-priority patent/WO2015031541A1/en
Application filed by Stemcentrx Inc filed Critical Stemcentrx Inc
Publication of IL244277A0 publication Critical patent/IL244277A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL244277A 2013-08-28 2016-02-24 Methods and preparations of attaching an antibody to a specific location IL244277A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361871173P 2013-08-28 2013-08-28
US201361871289P 2013-08-28 2013-08-28
PCT/US2014/053014 WO2015031541A1 (en) 2013-08-28 2014-08-27 Novel sez6 modulators and methods of use
PCT/US2014/053310 WO2015031698A1 (en) 2013-08-28 2014-08-28 Site-specific antibody conjugation methods and compositions

Publications (1)

Publication Number Publication Date
IL244277A0 true IL244277A0 (en) 2016-04-21

Family

ID=52587354

Family Applications (1)

Application Number Title Priority Date Filing Date
IL244277A IL244277A0 (en) 2013-08-28 2016-02-24 Methods and preparations of attaching an antibody to a specific location

Country Status (17)

Country Link
US (2) US10035853B2 (enExample)
EP (2) EP3892294A1 (enExample)
JP (3) JP2016531915A (enExample)
KR (1) KR20160044042A (enExample)
CN (1) CN105848671B (enExample)
AU (1) AU2014312215B2 (enExample)
BR (1) BR112016004242A8 (enExample)
CA (1) CA2922547C (enExample)
CL (2) CL2016000465A1 (enExample)
ES (1) ES2871418T3 (enExample)
IL (1) IL244277A0 (enExample)
MX (1) MX377339B (enExample)
PE (1) PE20160674A1 (enExample)
PH (1) PH12016500391A1 (enExample)
RU (1) RU2016111131A (enExample)
SG (1) SG11201601424PA (enExample)
WO (1) WO2015031698A1 (enExample)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
AU2011295715B9 (en) 2010-09-03 2017-02-23 Abbvie Stemcentrx Llc Novel modulators and methods of use
CA2809864A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
KR20140031175A (ko) 2010-12-08 2014-03-12 스템 센트알엑스 인코포레이티드 신규 조절제 및 용법
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
NZ631197A (en) 2012-02-24 2017-05-26 Abbvie Stemcentrx Llc Anti sez6 antibodies and methods of use
ES2645272T3 (es) 2012-02-24 2017-12-04 Abbvie Stemcentrx Llc Moduladores de DLL3 y procedimientos de utilización
CA2900764A1 (en) 2013-02-08 2014-08-14 Stemcentrx, Inc. Novel multispecific constructs
US9968687B2 (en) 2013-02-22 2018-05-15 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
CN105792836A (zh) 2013-08-28 2016-07-20 施特姆森特克斯股份有限公司 新型sez6调节剂以及应用方法
PE20160674A1 (es) 2013-08-28 2016-07-21 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
AR098221A1 (es) 2013-11-04 2016-05-18 Pfizer Conjugados de anticuerpo anti-efna4-fármaco
BR112016010169A2 (pt) 2013-11-06 2017-12-05 Stemcentrx Inc anticorpos anticlaudina e métodos de uso
CN106104273A (zh) 2013-12-12 2016-11-09 施特姆森特克斯股份有限公司 新型抗dpep3抗体和使用方法
MX2016010677A (es) 2014-02-21 2017-04-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma.
MX375284B (es) 2014-04-30 2025-03-06 Pfizer Conjugados de anticuerpo-fármaco anti-proteína tirosina quinasa 7 (anti-ptk7).
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
EP3285807A4 (en) * 2015-04-21 2018-12-26 Abbvie Stemcentrx LLC Calicheamicin constructs and methods of use
UA129321C2 (uk) 2015-06-19 2025-03-19 Ейсай Р&Д Менеджмент Ко., Лтд. Cys80-кон'юговані імуноглобуліни
HK1257056A1 (zh) * 2015-08-20 2019-10-11 Abbvie Stemcentrx Llc 抗dll3抗体药物缀合物以及使用方法
EP3374383A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia AMYLOID BETA EPITOPES AND ANTIBODIES
AU2016354688B2 (en) 2015-11-09 2021-12-16 The University Of British Columbia Epitopes in Amyloid beta mid-region and conformationally-selective antibodies thereto
EP3374379A4 (en) 2015-11-09 2019-05-15 The University Of British Columbia N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES
RU2754369C2 (ru) 2016-03-02 2021-09-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Конъюгаты антитело-лекарственное средство на основе эрибулина и способы применения
KR102514317B1 (ko) 2016-04-15 2023-03-27 마크로제닉스, 인크. 신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
JP2019522960A (ja) 2016-04-21 2019-08-22 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗ｂｍｐｒ１ｂ抗体及び使用方法
WO2017201442A1 (en) * 2016-05-20 2017-11-23 Abbvie Stemcentrx Llc Anti-dll3 drug conjugates for treating tumors at risk of neuroendocrine transition
US12071472B2 (en) 2016-07-18 2024-08-27 The University Of British Columbia Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
WO2018119351A1 (en) 2016-12-23 2018-06-28 Bluefin Biomedicine, Inc. Anti-sez6l2 antibodies and antibody drug conjugates
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
EP3424538A1 (en) 2017-07-06 2019-01-09 Centre National De La Recherche Scientifique Bioconjugates with a controlled degree of conjugation, their process of preparation, and the reagents for their preparation
EP3424528A1 (de) * 2017-07-07 2019-01-09 AVA Lifescience GmbH Biologische bindemoleküle
US12286469B2 (en) 2017-07-18 2025-04-29 The University Of British Columbia Humanized antibodies binding to amyloid-beta (A-beta)
EP3687546A4 (en) 2017-09-26 2022-01-26 The Trustees Of The University Of Pennsylvania COMPOSITIONS AND METHODS FOR TREATING HEART DISEASE WITH REDIRECTED T-LYMPHOCYTE IMMUNOTHERAPIES
WO2019074934A1 (en) * 2017-10-09 2019-04-18 Healthtell Inc. IMMUNOGENS FOR DIRECTED IMMUNE RESPONSE AND ANTIBODIES THEREFROM
WO2019169229A1 (en) * 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
WO2019191630A1 (en) 2018-03-29 2019-10-03 Abbvie Inc. Selective reduction of antibodies
DK3710485T3 (da) 2018-05-30 2021-05-10 Abbvie Stemcentrx Llc Anti-sez6-antistof-lægemiddelkonjugater og anvendelsesfremgangsmåder
US20220040320A1 (en) * 2018-12-21 2022-02-10 Seagen Inc. Adcs with thiol multiplex linkers
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
JP7232925B2 (ja) 2019-02-15 2023-03-03 ウーシー バイオロジクス アイルランド リミテッド 改善された均一性を有する抗体薬物コンジュゲートの調製するプロセス
EP4017529A4 (en) * 2019-08-22 2024-03-13 Cidara Therapeutics, Inc. FIELDS FC VARIANTS AND THEIR USES
CN114746438A (zh) 2019-09-23 2022-07-12 宾夕法尼亚大学董事会 通过靶向成纤维细胞激活蛋白(fap)使肿瘤组织破裂
CA3151438A1 (en) 2019-09-23 2021-04-01 Ellen PURE Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (fap)
KR20220131527A (ko) * 2020-01-10 2022-09-28 크링 바이오테라퓨틱스 비.브이. 상피 카드헤린-특이적 항체
US11179473B2 (en) 2020-02-21 2021-11-23 Silverback Therapeutics, Inc. Nectin-4 antibody conjugates and uses thereof
MX2022010657A (es) * 2020-02-27 2022-09-23 Phanes Therapeutics Inc Anticuerpos conjugados con moleculas de acidos grasos y usos de los mismos.
WO2022051223A1 (en) * 2020-09-02 2022-03-10 The Feinstein Institutes For Medical Research Use of sars-cov-2 receptor binding motif (rbm)-reactive monoclonal antibodies to treat covid-19
CN118221804B (zh) * 2021-01-18 2025-02-07 上海药明合联生物技术有限公司 工程化抗体和包含工程化抗体的抗体-药物偶联物
US12365739B2 (en) * 2021-03-24 2025-07-22 Wake Forest University Health Sciences Monoclonal antibodies to angiotensin-(1-12), compositions including the same, and methods of use thereof
WO2024046455A1 (en) * 2022-09-01 2024-03-07 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Methods for preparing antibody-drug conjugates
AU2024265570A1 (en) * 2023-04-29 2025-12-04 Innovent Biologics (Suzhou) Co., Ltd. Modified antibodies, antibody fragments thereof, and antibody-drug conjugates
EP4548936A1 (en) * 2023-10-30 2025-05-07 BioNTech SE Antibody-drug conjugates having a tailor-made drug-to-antibody ratio
WO2025171294A1 (en) * 2024-02-07 2025-08-14 University Of Massachusetts Lysosome-targeting chimeras and methods of use
WO2025179135A1 (en) * 2024-02-23 2025-08-28 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer using targeted pore-forming agents
WO2025217258A1 (en) * 2024-04-09 2025-10-16 The Rockefeller University Nptx1 antibodies
CN120365421B (zh) * 2025-04-24 2025-11-04 成都古格尔生物技术有限公司 一种特异性抗sez6靶点的全人源抗体及其制备方法和应用

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR901464A (fr) 1943-01-23 1945-07-27 Boehringer & Soehne Gmbh Procédé d'obtention de vanilline
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS58180487A (ja) 1982-04-16 1983-10-21 Kyowa Hakko Kogyo Co Ltd 抗生物質ｄｃ−８１およびその製造法
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4703004A (en) 1984-01-24 1987-10-27 Immunex Corporation Synthesis of protein with an identification peptide
JP2532858B2 (ja) 1985-04-01 1996-09-11 セルテツク リミテツド 形質転換したミエロ―マ細胞系
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them
US5879936A (en) 1988-04-18 1999-03-09 Aluguisse Holding A.G. Recombinant DNA methods, vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
ES2162789T3 (es) 1990-06-29 2002-01-16 Large Scale Biology Corp Produccion de melanina por microorganismos transformados.
ATE185601T1 (de) 1990-07-10 1999-10-15 Cambridge Antibody Tech Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ES2113940T3 (es) 1990-12-03 1998-05-16 Genentech Inc Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas.
US5191066A (en) 1990-12-07 1993-03-02 Abbott Laboratories Site-specific conjugation of immunoglobulins and detectable labels
EP0732402A3 (en) 1990-12-14 1997-05-21 Cell Genesys Inc Chimeric chains for transduction of receptor-linked signaling pathways
CA2105300C (en) 1991-03-01 2008-12-23 Robert C. Ladner Process for the development of binding mini-proteins
IE921169A1 (en) 1991-04-10 1992-10-21 Scripps Research Inst Heterodimeric receptor libraries using phagemids
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU668423B2 (en) 1992-08-17 1996-05-02 Genentech Inc. Bispecific immunoadhesins
DE122004000036I1 (de) 1992-11-13 2005-07-07 Biogen Idec Inc Therapeutische Verwendung von chimerischen und markierten Antik¦rper gegen menschlichen B Lymphozyt beschr{nkter Differenzierung antigen f}r die Behandlung von B-Zell-Lymphoma.
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
AU3382595A (en) 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
DE69626849T2 (de) 1995-12-22 2003-12-24 Bristol-Myers Squibb Co., Princeton Verzweigte hydrazongruppen enthaltende kuppler
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
KR100497017B1 (ko) 1996-03-22 2005-11-29 휴먼 게놈 사이언시즈, 인코포레이티드 고사유도분자ii
US6870033B1 (en) * 1997-02-21 2005-03-22 Genentech, Inc. Antibody fragment-polymer conjugates and humanized anti-IL-8 monoclonal antibodies
US20030180784A1 (en) 1997-04-04 2003-09-25 Millennium Pharmaceuticals, Inc. Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
US6753165B1 (en) 1999-01-14 2004-06-22 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
ES2303358T3 (es) 1997-11-03 2008-08-01 Human Genome Sciences, Inc. Vegi, un inhibidor de la angiogenesis y el crecimiento tumoral.
ATE531812T1 (de) 1997-12-05 2011-11-15 Scripps Research Inst Humanisierung von nager-antikörpern
AU2559799A (en) 1998-01-22 1999-08-09 Genentech Inc. Antibody fragment-polymer conjugates and humanized anti-il-8 monoclonal antibodies and uses of same
ES2260570T3 (es) 1998-08-27 2006-11-01 Spirogen Limited Pirrolobenziodiazepinas dimericas.
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
US20040067490A1 (en) 2001-09-07 2004-04-08 Mei Zhong Therapeutic polypeptides, nucleic acids encoding same, and methods of use
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6908748B2 (en) 1999-07-29 2005-06-21 Kenji Sobue Genes associated with the maintenance of differentiation of smooth muscle cells
WO2001012664A2 (en) 1999-08-19 2001-02-22 Chiron Corporation Notch receptor ligands and uses thereof
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
JP2003530847A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
EP1290026A2 (en) * 2000-04-28 2003-03-12 Eli Lilly And Company Human sez6 nucleic acids and polypeptides
WO2002014358A2 (en) 2000-08-11 2002-02-21 Eli Lilly And Company Novel secreted proteins and their uses
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
ES2727425T3 (es) 2000-12-12 2019-10-16 Medimmune Llc Moléculas con semividas prolongadas, composiciones y usos de las mismas
US6362331B1 (en) 2001-03-30 2002-03-26 Council Of Scientific And Industrial Research Process for the preparation of antitumor agents
US20030211991A1 (en) 2001-04-17 2003-11-13 Su Eric Wen Human sez6 nucleic acids and polypeptides
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
AU2003217930A1 (en) 2002-03-04 2003-09-22 Medimmune, Llc The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
DK2364996T3 (en) 2002-09-27 2017-02-06 Xencor Inc Optimized Fc variants and methods for their formation
ATE502051T1 (de) 2002-10-16 2011-04-15 Purdue Pharma Lp Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
WO2004042017A2 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1419786A1 (en) 2002-11-13 2004-05-19 Bracco Imaging S.p.A. Method for the selective and quantitative functionalization of immunoglobulin fab fragments, conjugate compounds obtained with the same and compositions thereof
GB0226593D0 (en) 2002-11-14 2002-12-24 Consultants Ltd Compounds
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
AU2004239301B2 (en) 2003-05-09 2010-08-19 Diadexus, Inc. OVR110 antibody compositions and methods of use
GB0315457D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
WO2005014854A1 (en) 2003-08-08 2005-02-17 Licentia, Ltd. Materials and methods for colorectal cancer screening, diagnosis, and therapy
EP1663306A2 (en) 2003-09-05 2006-06-07 Genentech, Inc. Antibodies with altered effector functions
GB0321295D0 (en) 2003-09-11 2003-10-15 Spirogen Ltd Synthesis of protected pyrrolobenzodiazepines
ZA200603619B (en) 2003-11-06 2008-10-29 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
GB0404577D0 (en) 2004-03-01 2004-04-07 Spirogen Ltd Pyrrolobenzodiazepines
PT2270010E (pt) 2004-03-01 2012-03-12 Spirogen Ltd Derivados de 11-hidroxi-5h-pirrolo[2,1-c][1,4]benzodiazepin- 5-ona como intermediários chave para a preparação de pirrolobenzodiazepinas substituídas em c2
CA2558399C (en) 2004-03-02 2015-05-19 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
US7189710B2 (en) 2004-03-30 2007-03-13 Council Of Scientific And Industrial Research C2-fluoro pyrrolo [2,1−c][1,4]benzodiazepine dimers
FR2869231B1 (fr) 2004-04-27 2008-03-14 Sod Conseils Rech Applic Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
US20070154889A1 (en) 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
ES2414460T3 (es) 2004-08-04 2013-07-19 Amgen Inc. Anticuerpos para Dkk-1
EP3088004B1 (en) 2004-09-23 2018-03-28 Genentech, Inc. Cysteine engineered antibodies and conjugates
CA2587589A1 (en) 2004-11-29 2006-06-22 Seattle Genetics, Inc. Engineered antibodies and immunoconjugates
AU2006239851B2 (en) 2005-04-26 2011-06-16 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US8633300B2 (en) * 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
GB0514779D0 (en) 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
EP2305811A1 (en) * 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
DE602006021205D1 (de) 2005-10-07 2011-05-19 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
US20070123448A1 (en) 2005-11-23 2007-05-31 The Hospital For Sick Children Novel chemical entities affecting neuroblastoma tumor-initiating cells
BRPI0620695A2 (pt) 2005-12-16 2011-11-22 Genentech, Inc método para tratar um tumor do tipo glioma, métodos de prognóstico e/ou diagnóstico de glioma, método de monitoramento ou diagnóstico, método para inibir o tamanho ou crescimento de um tumor do tipo glioma, métodos para tratar terapeuticamente, método para determinar o nìvel de expressão de marcadores determinantes de glioma ("gdm") de pn, prolif ou mes, método para prognosticar o tempo de sobrevida, método para diagnosticar a severidade de um tumor do tipo glioma e uso
EP1973945A4 (en) 2006-01-16 2009-11-18 Compugen Ltd NEW NUCLEOTIDE AND AMINO ACID SEQUENCES AND METHOD FOR THEIR APPLICATION IN DIAGNOSIS
SI1813614T1 (sl) 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
WO2007103114A2 (en) 2006-03-07 2007-09-13 The Brigham & Women's Hospital, Inc. Notch inhibition in the treatment or prevention of atherosclerosis
ES2444010T3 (es) * 2006-05-30 2014-02-21 Genentech, Inc. Anticuerpos e inmunoconjugados y usos de los mismos
CA2658003A1 (en) 2006-06-06 2007-12-21 University Of Tennessee Research Foundation Compositions enriched in neoplastic stem cells and methods comprising same
US20080220448A1 (en) 2006-09-01 2008-09-11 Blincko Stuart J Antigenic protein conjugates and process for preparing same
PL3207941T6 (pl) 2006-09-07 2020-11-16 Scott & White Memorial Hospital Sposoby i kompozycje oparte na koniugacie ludzkiej interleukiny (IL)-3 z toksyną błoniczą
US7825267B2 (en) 2006-09-08 2010-11-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Synthesis of FR901464 and analogs with antitumor activity
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
EP2078731A4 (en) 2006-10-20 2012-08-01 Forerunner Pharma Res Co Ltd ANTI-HB-EGF ANTIBODY AS PHARMACEUTICAL COMPOSITION CONTAINING ACTIVE SUBSTANCE
US8309354B2 (en) 2007-01-22 2012-11-13 Macrogenics West, Inc. Human cancer stem cells
CN101687037B (zh) 2007-05-08 2013-07-10 健泰科生物技术公司 半胱氨酸改造的抗muc16抗体和抗体药物偶联物
EP2145021A2 (en) 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
EP2190481B1 (en) 2007-07-17 2014-12-24 The General Hospital Corporation Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof
EP2022848A1 (en) 2007-08-10 2009-02-11 Hubrecht Institut A method for identifying, expanding, and removing adult stem cells and cancer stem cells
US8865875B2 (en) 2007-08-22 2014-10-21 Medarex, L.L.C. Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
KR20100052545A (ko) 2007-08-28 2010-05-19 바이오겐 아이덱 엠에이 인코포레이티드 Ｉｇｆ―１ｒ의 다중 에피토프에 결합하는 조성물
CA2698809C (en) 2007-09-14 2023-10-17 Amgen Inc. Homogeneous antibody populations
US20090155255A1 (en) 2007-09-27 2009-06-18 Biogen Idec Ma Inc. Cd23 binding molecules and methods of use thereof
WO2009052249A1 (en) 2007-10-19 2009-04-23 Genentech, Inc. Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
US20110091524A1 (en) 2007-12-18 2011-04-21 Yan Wang Biomarkers for sensitivity to anti-igf1r therapy
AU2009205995B2 (en) * 2008-01-18 2014-04-03 Medimmune, Llc Cysteine engineered antibodies for site-specific conjugation
US8557965B2 (en) 2008-04-07 2013-10-15 Ablynx N.V. Single variable domains against notch pathway members
US9272029B2 (en) * 2009-03-26 2016-03-01 Ibc Pharmaceuticals, Inc. Interferon lambada-antibody complexes
BRPI0910622A2 (pt) * 2008-04-25 2020-03-10 Dyax Corp. ANTICORPOS CONTRA FcRn E USOS DOS MESMOS
US8384551B2 (en) 2008-05-28 2013-02-26 MedHab, LLC Sensor device and method for monitoring physical stresses placed on a user
US20100162416A1 (en) 2008-09-29 2010-06-24 Stemlifeline, Inc. Multi-stage stem cell carcinogenesis
JP2012508577A (ja) 2008-11-12 2012-04-12 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 表現型を決定するためのエキソソームの使用方法およびそのシステム
US8788213B2 (en) 2009-01-12 2014-07-22 Intrexon Corporation Laser mediated sectioning and transfer of cell colonies
JP2010173975A (ja) * 2009-01-30 2010-08-12 Apro Life Science Institute Inc タンパク質のリフォールディング組成物
EP2399129B1 (en) 2009-02-20 2015-11-25 Michael P. Lisanti A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm
EP3674317B1 (en) 2009-03-19 2024-12-11 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US20110020221A1 (en) 2009-04-09 2011-01-27 The Johns Hopkins University Cancer stem cell expression patterns and compounds to target cancer stem cells
WO2011002029A1 (ja) 2009-07-03 2011-01-06 国立大学法人東京大学 癌細胞の存否を判定する方法および癌患者の予後を判定する方法
HRP20180952T1 (hr) 2010-01-29 2018-07-27 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antitijelo
PT2536399T (pt) 2010-02-21 2020-02-06 Bayer Healthcare Llc Método para ativação e conjugação de biomoléculas
WO2011108714A1 (ja) 2010-03-04 2011-09-09 中外製薬株式会社 抗体定常領域改変体
TWI540136B (zh) 2010-04-15 2016-07-01 梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
ES2623057T3 (es) 2010-04-15 2017-07-10 Medimmune Limited Pirrolobenzodiazepinas usadas para tratar enfermedades proliferativas
CN107019804A (zh) 2010-04-15 2017-08-08 西雅图基因公司 靶向吡咯并苯并二氮杂卓结合物
GB201006340D0 (en) 2010-04-15 2010-06-02 Spirogen Ltd Synthesis method and intermediates
WO2011156328A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
US20120100560A1 (en) 2010-07-23 2012-04-26 The Johns Hopkins University Device for capture, enumeration, and profiling of circulating tumor cells
CA2809864A1 (en) 2010-09-03 2012-03-08 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US20130061340A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
WO2013119964A2 (en) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification and enrichment of cell subpopulations
US20130061342A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc. Identification and Enrichment of Cell Subpopulations
US9778264B2 (en) 2010-09-03 2017-10-03 Abbvie Stemcentrx Llc Identification and enrichment of cell subpopulations
EP2617730B1 (en) * 2010-09-17 2018-03-07 National Institute of Advanced Industrial Science And Technology Lung cancer differential marker
EA201790850A1 (ru) 2010-09-29 2017-11-30 Эдженсис, Инк. Конъюгаты антитело-лекарственное средство (adc), связывающиеся с белками 191p4d12
WO2012064733A2 (en) 2010-11-09 2012-05-18 Medimmune, Llc Antibody scaffold for homogenous conjugation
US20130259806A1 (en) 2010-12-09 2013-10-03 David Light Dimeric molecular complexes with free cysteine residues and conjugates thereof
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US20140026234A1 (en) 2011-01-28 2014-01-23 Thomas Jefferson University Biomarkers and their uses in cancer detection and therapy
PT2675480T (pt) 2011-02-15 2019-04-15 Immunogen Inc Métodos para preparação de conjugados
MX347590B (es) 2011-03-02 2017-05-03 Roche Glycart Ag Anticuerpos del cea.
US20140302042A1 (en) 2011-07-01 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
MX341524B (es) 2011-09-20 2016-08-24 Medimmune Ltd Pirrolobenzodiazepinas como compuestos pbd dimericos asimetricos para inclusion en conjugados dirigidos.
MX341523B (es) 2011-10-14 2016-08-24 Medimmune Ltd Pirrolobenzodiazepinas.
HRP20151374T1 (hr) 2011-10-14 2016-01-15 Medimmune Limited Pirolobenzodiazepini i njihovi konjugati
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
RS60499B1 (sr) 2011-12-20 2020-08-31 Medimmune Llc Modifikovani polipeptidi za bispecifične skelete antitela
US11147852B2 (en) 2011-12-23 2021-10-19 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
JP6228551B2 (ja) * 2012-01-03 2017-11-08 インビクタス オンコロジー プライベート リミテッド リガンド−標的指向分子およびその方法
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
NZ631197A (en) * 2012-02-24 2017-05-26 Abbvie Stemcentrx Llc Anti sez6 antibodies and methods of use
ES2645272T3 (es) 2012-02-24 2017-12-04 Abbvie Stemcentrx Llc Moduladores de DLL3 y procedimientos de utilización
US20150071947A1 (en) 2012-03-09 2015-03-12 Verastem, Inc. Methods of identifying gene isoforms for anti-cancer treatments
US9504756B2 (en) 2012-05-15 2016-11-29 Seattle Genetics, Inc. Self-stabilizing linker conjugates
JP6273205B2 (ja) 2012-10-05 2018-01-31 協和発酵キリン株式会社 ヘテロダイマータンパク質組成物
WO2014057072A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Synthesis and intermediates of pyrrolobenzodiazepine derivatives for conjugation
CA2941485C (en) 2012-10-12 2018-06-12 Philip Wilson Howard Pyrrolobenzodiazepines and conjugates thereof
EA201591465A1 (ru) 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Специфичные участки для модификации антител для получения иммуноконъюгатов
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
US9968687B2 (en) * 2013-02-22 2018-05-15 Abbvie Stemcentrx Llc Anti-DLL3 antibody drug conjugates
KR20160018579A (ko) 2013-06-04 2016-02-17 싸이톰스 테라퓨틱스, 인크. 활성화가능 항체를 접합하기 위한 조성물 및 방법
CN105792836A (zh) 2013-08-28 2016-07-20 施特姆森特克斯股份有限公司 新型sez6调节剂以及应用方法
EP3038659A4 (en) 2013-08-28 2017-07-26 AbbVie Stemcentrx LLC Engineered anti-dll3 conjugates and methods of use
PE20160674A1 (es) 2013-08-28 2016-07-21 Stemcentrx Inc Metodos de conjugacion de anticuerpos especificos de sitio y composiciones
EP3054983B1 (en) 2013-10-11 2019-03-20 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
EP3054985B1 (en) 2013-10-11 2018-12-26 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
EP3054984A1 (en) 2013-10-11 2016-08-17 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
HK1231400A1 (zh) 2014-02-11 2017-12-22 Seattle Genetics, Inc. 蛋白质的选择性还原
MX2016010677A (es) 2014-02-21 2017-04-10 Abbvie Stemcentrx Llc Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma.
JP6137080B2 (ja) 2014-07-28 2017-05-31 Ｊｆｅスチール株式会社 スラブ鍛造方法
EP3209334A2 (en) 2014-10-20 2017-08-30 Igenica Biotherapeutics, Inc. Novel antibody-drug conjugates and related compounds, compositions, and methods of use

Also Published As

Publication number Publication date
US20180346565A1 (en) 2018-12-06
JP2020063271A (ja) 2020-04-23
JP2016531915A (ja) 2016-10-13
AU2014312215B2 (en) 2020-02-27
ES2871418T3 (es) 2021-10-28
EP3038644B1 (en) 2021-04-07
RU2016111131A (ru) 2017-10-03
WO2015031698A8 (en) 2015-12-03
MX377339B (es) 2025-03-06
CN105848671A (zh) 2016-08-10
JP2021120382A (ja) 2021-08-19
RU2016111131A3 (enExample) 2018-11-12
BR112016004242A2 (pt) 2017-10-17
BR112016004242A8 (pt) 2018-06-12
CN105848671B (zh) 2019-12-13
EP3892294A1 (en) 2021-10-13
EP3038644A1 (en) 2016-07-06
CL2016000465A1 (es) 2016-12-16
CA2922547A1 (en) 2015-03-05
PH12016500391A1 (en) 2016-05-16
CA2922547C (en) 2020-03-10
SG11201601424PA (en) 2016-03-30
MX2016002547A (es) 2016-06-17
WO2015031698A1 (en) 2015-03-05
CL2017001295A1 (es) 2018-02-09
US20160176964A1 (en) 2016-06-23
EP3038644A4 (en) 2017-08-30
US10035853B2 (en) 2018-07-31
KR20160044042A (ko) 2016-04-22
PE20160674A1 (es) 2016-07-21

Similar Documents

Publication Publication Date Title
IL244277A0 (en) Methods and preparations of attaching an antibody to a specific location
IL273205A (en) Preparations and methods
ZA201706241B (en) Anti-cxcr4 antibodies and antibody-drug conjugates
IL240438A0 (en) New antibody conjugates and their uses
IL243425A0 (en) Formulations and methods based on antibodies
GB2520795B (en) Compositions and methods
IL240517A0 (en) Antibodies against b7–h4 and immunoconjugates
IL245040A0 (en) Antibodies against pdgfr-beta and their uses
IL243974B (en) Antibodies against –prlr and uses
IL240354A0 (en) Antibodies against il-33 and their uses
PT2968552T (pt) Anticorpo dos agentes alvo, combinações e uso para os mesmos
SG10201709715RA (en) Anti-b7-h5 antibodies and their uses
SMT202100394T1 (it) Anticorpo anti-her2 e relativo coniugato
IL241079A0 (en) Antibodies against pesidine and their uses
GB201308072D0 (en) Compositions and methods
GB201305813D0 (en) Compositions and methods
IL245437A0 (en) Antibodies against efna4 and antibody-drug pairs
GB201322617D0 (en) Methods and compositions
GB201312393D0 (en) Compositions and Methods